Safety and immunogenicity of Ervebo® and Zabdeno® booster vaccines against Ebola virus following previous vaccination with the Zabdeno®/Mvabea® or Ervebo® vaccine schedules in DRC

Project Details

AcronymEBO BOOST_MSD
StatusActive
Effective start/end date19/01/2418/01/27

Funding

  • Merck Sharp & Dohme bv: €275,189.95